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Musculoskeletal oncology remains a dynamic and interdisciplinary field of orthopaedic surgery. This Guest Editorial will include new developments based on articles from major journals (including articles that have been electronically published ahead of print) as well as updates from recent professional meetings and developments in the field. I have chosen to also present selected articles in tables to increase their accessibility and to separately highlight other developments.
Bone Tumors (Table I) Bone Metastases Cancer remains the second leading cause of death in the United States and many industrialized nations 1 . The skeletal system is the third most common site of metastatic disease (after the lung and liver), with >250,000 individuals per year in the United States estimated to be living with skeletal metastases. Although only a portion of these patients require intervention, the large number of patients involved makes skeletal metastases a clinically relevant topic for all surgeons.
The treatment of metastatic disease is generally palliative in nature and is focused on maximizing both duration and quality of life. Relatively little information exists with regard to modern patient-reported outcomes in these patients. Blank et al. reported outcomes in patients with operatively treated metastasis using the PROMIS (Patient-Reported Outcomes Measurement Information System), a U.S. National Institutes of Health (NIH)-developed general patient-reported outcome tool becoming standard in many areas of oncology, orthopaedic surgery, and medicine in general, and reported improved physical function and pain postoperatively 2 . Although it is a small study, it lays the groundwork for what will likely become standard reporting in the future and demonstrates improved patient outcomes with intervention using the most modern available patient outcome instrument.
The most common location of symptomatic skeletal metastases is about the hip, and several authors have recently reported on this topic. After analyzing a U.S. Veterans Admin-istration database, Philipp et al. provided strong data that patients with femoral metastases treated prophylactically have a lower risk of death (hazard ratio [HR], 0.75) than similar patients treated after fracture 3 . This confirms the clinical intuition and experience of many surgeons and provides strong justification for prophylactic treatment. Plummer et al. 4 and Rowell et al. 5 reported good clinical results using dual-mobility 4 and cement and cage reconstructions of periacetabular metastases 5 , outlining treatment protocols for these patients that are accessible to all experienced hip surgeons.
Primary Bone Tumors
The most wide-reaching contemporary development in the field of bone tumors has been the implementation of new staging criteria from the AJCC (American Joint Committee on Cancer) Cancer Staging Manual, Eighth Edition, for malignant bone tumors 6 . Although these staging criteria have remained largely static for many years, clinicians have long recognized that pelvic and spinal bone tumors had adverse clinical outcomes compared with extremity tumors. A recent analysis of 5,671 patients with staging and survival data from 2002 to 2008 highlighted 2 limitations of traditional bone tumor staging 6 . First, patients with pelvic or spinal tumors had poorer survival compared with patients with a similar-stage extremity bone tumor. Second, traditional staging criteria failed to discriminate outcomes between patients with different stages of disease in the pelvis or spine. This led to the first-ever incorporation of the anatomic location into the staging criteria for bone tumors. Beginning in the AJCC staging of bone tumors, different criteria are applied to extremity, pelvic (inclusive of the sacrum), and mobile spinal tumors. These changes represent a first step toward gathering data to better define the proper staging and prognosis of these tumors.
A number of other interesting articles have appeared recently. Bongers et al. used the machine learning SORG (Skeletal Oncology Research Group) algorithm trained on data from the U.S. National Cancer Institute's Surveillance, This study helps clinicians to tailor the use of radiation therapy to patients who may derive maximum benefit Istl 25 Systematic review and meta-analysis of chemotherapy and survival in soft-tissue sarcoma Pooled analysis of 10 studies (3,157 patients) showed no clear benefit to chemotherapy for soft-tissue sarcoma
The role of chemotherapy in softtissue sarcomas continues to be investigational Wigge 26 Impact of surgery in patients with metastatic soft-tissue sarcoma Metastatectomy and progression-free intervals were predictive factors for prolonged survival
Note that resection of nonpulmonary metastases appears to be valuable 9 , and Chan et al. provided further data to question the benefit of chemotherapy in periosteal osteosarcoma 10 . Finally, Tsukamoto et al. showed that curettage and joint salvage (compared with resection and reconstruction) in patients with giant cell tumors presenting with pathologic fractures yielded improved function and lower overall complication rates 11 . As pathologic fracture is a common and difficult presentation of these tumors that has traditionally prompted a strong consideration of resection, that article helped to inform and potentially alter the treatment of locally advanced giant cell tumors.
Bone Tumor Resection and Reconstruction
A number of studies have investigated specific bone tumor resection and reconstruction techniques (rather than specific tumor types). Several studies have examined the application of new technologies in the resection of bone tumors. Bosma et al. provided 2 studies in this area. In 1 study, they critically examined the benefit of navigation technology in pelvic and sacral resections; navigation improved the ability to obtain negative bone (but not softtissue) margins in a consecutive cohort study 12 . This group also studied the benefit of combining navigation with custom cutting guides in a cadaveric validation study, in which custom cutting guides (with or without navigation) pro-vided the highest accuracy 13 . A clinical series by Park et al. demonstrated a maximum cutting error of 3 mm using custom cutting guides 14 . These studies showed the scientific validity of techniques beyond early case reports or proof-ofconcept series in these areas. Finally, Cho et al. reported a preliminary study of augmented reality resections in simulated tumors, with improved resection accuracy even for less experienced surgeons 15 .
Other authors have examined different reconstruction techniques. Aponte-Tinao et al. provided a definitive series on the ‡10-year survival of bulk allografts for the femur and tibia (showing 60% graft survival in 166 patients) 16 . However, when stratified by location, proximal tibial osteoarticular grafts fared poorly. Puri et al. similarly reported a series of 70 patients with diaphyseal tumors reconstructed using an irradiated autograft with 75% graft survival 17 . Although this technique is less commonly employed in contemporary North American practice, these results inform surgeons of this technique as a viable treatment option in a large series. (Table II) Soft-Tissue Sarcomas A number of important publications on soft-tissue sarcomas have become available recently. Several studies have shown different aspects of outcomes. Oh et al. reported the functional outcomes of patients with a limb-salvage surgical procedure for soft-tissue sarcoma 18 . Results continued to improve through 2 years and then plateaued, with the best results in younger patients. These data highlighted the time-dependent recovery from limb-salvage surgical procedures.
Soft-Tissue Tumors
Unplanned excisions continue to be seen in roughly 20% of soft-tissue sarcomas. Traub et al. analyzed a large series of high-risk patients (AJCC Stage-III tumors: large, deep, and high-grade) and found that patients undergoing unplanned excisions had higher amputation rates and more complex surgical procedures 19 . However, even in this very high-risk group, ultimate oncologic outcomes (recurrence, metastases, survival) were similar to patients undergoing planned resections. Similarly, Wilke et al. reported the PROMIS outcomes of patients following planned or unplanned soft-tissue sarcoma resections, with similar overall patientreported outcomes 20 . Many surgeons have naturally assumed 33 20-year experience of reconstruction after extremity soft-tissue sarcoma resection Series of 136 patients; wound complications seen in 53%; the mean time to healing was 13 weeks Complications, healing time, and oncologic outcomes were independent of reconstructive method that the more complex treatment of patients with prior unplanned excision would lead to inferior patient-reported outcomes. This study calls this into question, assuming that experience shows us that the PROMIS instruments are sensitive evaluations of patients with sarcoma. Specific patient populations merit consideration in these disease processes. Gingrich et al. critically evaluated the results of extremity soft-tissue sarcomas in patients who were ‡74 years of age, a population in which the risk/benefit ratio of aggressive treatment is less clear 21 . Surgically treated patients had increased 90-day mortality but improved overall survival compared with nonoperatively treated patients. Similarly, the management of distal extremity tumors is complex. Mattei et al. showed that, after basic risk adjustment, size did not influence survival or recurrence 22 . In other words, distal extremity sarcomas displayed equivalent biologic behavior to proximal tumors. Finally, Montgomery et al. provided a timely analysis of the impact of obesity on soft-tissue sarcoma presentation and management 23 . Obese patients presented with larger tumors (presumably due to the difficulty in discovering them by patients and clinicians alike), required more complex wound closures, and sustained more complications than non-obese patients. These results become increasingly important in properly risk-stratifying patients and outcomes.
The role of adjuvant therapies in the management of soft-tissue sarcomas continues to generate study. Callegaro et al. provided an analysis of the value of radiotherapy and chemotherapy in soft-tissue sarcomas stratified by subtype 24 . Myxoid liposarcomas, vascular sarcomas, and myxofibrosarcomas had the greatest benefit from radiation therapy in local control rates (with no difference in overall survival). Chemotherapy resulted in a 5% survival benefit. In contrast, Istl et al. provided a systematic review and meta-analysis and found no clear survival benefit from chemotherapy in soft-tissue sarcomas 25 . Clearly, ongoing prospective, randomized trials will be needed to definitively resolve this issue. Meanwhile, chemotherapy remains investigational in the treatment of these diseases; although radiation therapy is also a default aspect of soft-tissue sarcoma care, Callegaro et al. questioned its role in many histologies.
Despite aggressive treatment, a number of patients with soft-tissue sarcoma will develop metastases. Wigge et al. reported on the benefit of a surgical procedure in patients with metastatic soft-tissue sarcoma 26 . The progression-free interval and metastatectomy were associated with prolonged survival. In a classic single histologic study, Outani et al. reported on 191 patients at the Royal Orthopaedic Hospital, Birmingham, England, with synovial sarcoma; there was a minimum 5-year follow-up of surviving patients 27 . Interestingly, diseasespecific survival fell from 76% at 5 years to 60% at 10 years; 5% of patients who were continually disease-free at 5 years developed late metastases, all in the lung. This study highlighted the propensity of synovial sarcoma for clinical events and mortality beyond the traditional 5-year oncologic end point.
Finally, Lazarides et al. reported an analysis of the National Cancer Database to assess the value of patients with soft-tissue sarcoma being treated at high-volume centers 28 . Although the majority of patients in their sample were treated at low-volume centers, patients treated at high-volume centers had a lower risk of mortality (HR, 0.81).
Benign Tumors
Most benign soft-tissue tumors are treated by function-sparing marginal resection, with good outcome and a low risk of symptomatic recurrence. Desmoid tumors are a stark exception to this rule. Because of disappointing and unpredictable results following surgical procedures, the clinical practice pattern in the care of desmoid tumors has shifted away from operative care. Van Broekhoven et al. analyzed the outcome of nonoperatively treated extra-abdominal and truncal desmoid tumors in a population-based study from the Netherlands 29 . As their database spanned from 1993 to 2013 (an era in which most patients were treated surgically), only 9% of the patient population was analyzed as initially treated nonoperatively. However, in these patients (many of whom had radiation or chemotherapy), 91% did not progress. This study adds to the growing experience of success in treating desmoid tumors (at least initially) nonoperatively.
Diffuse tenosynovial giant cell tumor (also known as diffuse pigmented villonodular synovitis) is also a challenging benign soft-tissue tumor to treat. Mastboom et al. helped to define this problem in a large, multi-institutional report from Europe that showed recurrence rates of nearly 50% in patients treated surgically for this disease 30 . Clearly, other treatment algorithms beyond a surgical procedure will be needed to adequately treat many of these patients.
An additional exception to the self-limited nature of most benign soft-tissue tumors is the Mazabraud syndrome (multiple myxomas associated with fibrous dysplasia). Majoor et al. reported a prevalence of Mazabraud syndrome of 2.2% in patients presenting with fibrous dysplasia; more importantly, myxoma recurrence was seen in 30% of operatively treated lesions 31 . This study, pooling data from 6 centers, will likely become the definitive article on this rare topic. complications and oncologic (rather than functional) outcomes 33 . Wound complications occurred in 53% of patients, but recurrence and metastasis were independent of the reconstruction method. Taken together, these 2 large studies provided reference benchmarks for complication profiles and reconstruction methodology.
Soft-Tissue Reconstruction
General Oncology Interest (Table III) Several studies of general interest in oncology have been published recently. Gurich et al. provided an interesting analysis of cognitive bias and how framing bias in particular can affect patient decisions for limb salvage rather than amputation 34 . This is certainly an area ripe for greater study in orthopaedic oncology.
Two other studies have provided more information on patient outcomes. Wilke et al. applied the PROMIS outcome measure to a population of patients with sarcoma and compared the results with those of the general population 35 . Although, as could be expected, patients with sarcoma had lower physical function, they actually had better depression scores compared with the general population. As mentioned above, the PROMIS measures are becoming established as an outcome measure in a wide range of medical care. In addition to the specific study results, this article demonstrated the application of these measures to a broad population of patients with sarcoma. Similarly, Piscione et al. reported on the new pediatric Toronto Extremity Salvage Score (pTESS) 36 . Although the TESS is well established in adult patients with extremity sarcoma, this helps to expand and validate the pediatric version of this instrument.
Infection and similar complications remain all too familiar to orthopaedic oncologists and their patients. Park et al. provided an analysis of the impact of malnutrition on complications in the treatment of bone sarcomas, with low albumin levels associated with an odds ratio (OR) as high as 4.69 for treatment complications 37 . Two other articles looked specifically at the microbiology of infections in patients with orthopaedic oncologic disease. Sanders et al. recently reported on the microbiology of pelvic periprosthetic infections 38 , and Ramsey et al. performed a similar analysis of infection following soft-tissue sarcoma treatment 39 . Both studies found microbiology patterns much different from typical orthopaedic infections. In both studies, most infections were polymicrobial and contained a large number of gramnegative and anaerobic organisms. These studies highlighted the different infection profile and treatment requirements of these patients compared with traditional orthopaedic operations.
Collaborative Trials and Resources
By its nature, orthopaedic oncology deals with rare conditions that are difficult to study prospectively. Recent efforts in collaborative research are nearing fruition to answer important clinical questions in our field. The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial is a prospective randomized trial investigating different antibiotic regimens in limb-salvage surgical procedures. Fifty-five sites in 12 countries completed enrolling nearly 600 patients in late 2019. This trial serves as a model for the collaborative and prospective investigation of a rare condition and will likely define postoperative antibiotic treatment for limb-salvage resections. This identifies a potentially modifiable risk factor to improve patient outcomes Sanders 38 Multiflora and gramnegative organisms predominate in pelvic prosthesis infections 78% of pelvic periprosthetic infections were polymicrobial and 62% of organisms were gram-negative species
This study should prompt reconsideration of antibiotic protocols for pelvic tumor surgical procedures Ramsey 39 Microbiology of infections after soft-tissue sarcoma treatment
Although Staphylococcus aureus was the most common organism, most infections were polymicrobial and 31% contained anaerobes
This study should prompt reconsideration of antibiotic protocols for soft-tissue sarcoma surgical procedures
The Orthopaedic Research and Education Foundation (OREF)-sponsored multi-institutional randomized trial of intramedullary rods compared with long-stemmed hemiarthroplasty for impending or completed subtrochanteric pathologic fractures has passed the halfway mark in accrual. This study will quantify the morbidity and functional outcome of these surgical treatments. As targeted therapies lengthen the survival of patients with metastatic bone disease, the question of which procedure should be selected will become more important, and this study will likely provide strong guidance on this topic.
To further collaborative study, the American Academy of Orthopaedic Surgeons (AAOS) and the Musculoskeletal Tumor Society (MSTS) have initiated a Musculoskeletal Tumor Registry Pilot Project at 6 academic centers to help to define the process for the widespread adoption of an orthopaedic oncology registry to parallel the successful American Joint Replacement Registry. Similarly, the MSTS has initiated and awarded sarcoma research awards in 2018 and 2019 focused on mechanistic sarcoma research with the support of the Sarcoma Strong Foundation.
Additional collaborative electronic resources are now available to clinicians. The SARCULATOR app, for example, provides immediate soft-tissue sarcoma prognosis in a free app format. Similarly, the PATHFx program provides immediate survival estimates to help to guide the care of patients with metastatic bone disease. It is available online to clinicians free of charge. Mankin was a founding member of the Musculoskeletal Tumor Society and a mentor to many generations of orthopaedic oncologists. He helped to pioneer the field of limb-salvage surgery and the use of allografts for tumor reconstruction and to initiate the Orthopaedic In-Training Examination and Recertification for board-certified surgeons 40 .
